Sever, Nejc, dr. med.
VIAF ID: 29157467940922321823 ( Personal )
Permalink: http://viaf.org/viaf/29157467940922321823
Preferred Forms
- 100 1 _ ‡a Sever, Nejc, ‡c dr. med.
Works
Title | Sources |
---|---|
Aplikacije za učenje pravilne izgovarjave | |
Biopsies from ulcer edge yield higher histological activity scores than biopsies next to ulcer in active ulcerative colitis | |
Bolezni žolčnih poti | |
Comparison of plasma exchange and insulin in non-severe acute hyperglyceridemic pancreatitis-a randomized study | |
DNA-based sputum cell image analysis for lung cancer in a clinical setting | |
Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label | |
Eozinofilne bolezni prebavil | |
Eozinofilni ezofagitis = Eosinophilic esophagitis | |
Kolagenozni gastritis | |
Korelacija med rezultatom klasične citologije in kvantitativne citometrije induciranega izkašljaja in brisa bukalne sluznice pri bolnikih s pljučnim rakom in bolnikih z dejavniki tveganja : [Prešernova naloga] | |
Peak ustekinumab concentration after intravenous loading dose predicts faecal calprotectin normalisation in Crohn's disease | |
Premalignant esophageal lesions-early detection and treatment | |
Radiofrequency ablation in patients with Barrett's esophagus | |
Rak požiralnika | |
Recommendations for Slovenian guidelines on the diagnosis and management of Barrett's esophagus | |
Small bowel capsule endoscopy - indications and an audit of procedures at the Department of Gastroenterology, UMC Ljubljana, 2012-2018 | |
Trough levels of golimumab at Week 6 predict drug retention rate in ulcerative colitis | |
Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease | |
Ustekinumab dosing individualization in Crohn's disease guided by a population pharmacokinetic-pharmacodynamic model | |
Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease |